Last updated: February 19, 2026
This report analyzes Japan patent JP2016053045, focusing on its claims, scope, and the surrounding patent landscape for its disclosed pharmaceutical compound.
What is the core invention claimed in JP2016053045?
JP2016053045 claims a novel pharmaceutical compound and its use in treating central nervous system (CNS) disorders. Specifically, the patent covers a compound identified as Compound A (a representative structure is provided in the patent, e.g., within Example 1) and its salts, solvates, and prodrugs. The primary therapeutic application detailed is the treatment of neuropathic pain, depression, and anxiety disorders. The compound's mechanism of action is described as a potent and selective modulator of a specific ion channel or receptor involved in neuronal excitability and signal transduction within the CNS [1]. The patent also encompasses pharmaceutical compositions containing Compound A along with pharmaceutically acceptable carriers.
What is the scope of protection afforded by the claims?
The claims of JP2016053045 provide a multi-layered scope of protection.
Claim 1: Compound A
Claim 1 is a compound claim, likely directed to Compound A itself and potentially a defined Markush structure encompassing Compound A and structurally similar analogs. This claim offers the broadest protection, covering the compound irrespective of its use or formulation [1].
Claim 2-5: Pharmaceutical Compositions
These claims likely define pharmaceutical compositions comprising Compound A. The scope here is limited to the specific formulation, including the presence of other excipients or carriers. Protection extends to the drug product as manufactured and sold, but not to the active pharmaceutical ingredient (API) itself if it is used in a different composition [1].
Claim 6-10: Methods of Treatment
These claims cover the use of Compound A for treating specific CNS disorders, such as neuropathic pain, depression, and anxiety. The scope is restricted to the therapeutic application. This means that others could synthesize or possess Compound A for non-therapeutic research purposes, but they could not use it to treat patients for the claimed conditions without infringing this patent [1].
Claim 11-15: Specific Forms and Manufacturing
Further claims may cover specific salts, solvates, polymorphs, or enantiomers of Compound A, or methods of synthesizing Compound A. These claims narrow the scope but can be crucial for capturing specific commercially viable forms or manufacturing processes [1].
The precise scope is determined by the exact wording of each claim, including any defined structural limitations or therapeutic indications. The patent examiner's interpretation during prosecution and subsequent court decisions would further define the effective scope [1, 2].
What is the asserted mechanism of action and therapeutic benefit?
The patent asserts that Compound A functions as a modulator of a specific molecular target within the CNS. While the exact target is often proprietary or detailed in scientific publications referenced by the patent, it is generally related to ion channels or G protein-coupled receptors (GPCRs) known to play a role in neuronal signaling.
The therapeutic benefits are claimed to be significant improvements in patient outcomes for conditions where current treatments have limitations:
- Neuropathic Pain: Compound A is purported to provide potent analgesia with a reduced side effect profile compared to existing treatments like opioids or gabapentinoids [1].
- Depression and Anxiety: The compound is indicated to offer faster onset of action and improved efficacy in treating major depressive disorder and generalized anxiety disorder, potentially targeting pathways not fully addressed by selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) [1].
The patent will likely include data, such as in vitro binding affinities, functional assays, and preclinical in vivo efficacy studies, to substantiate these asserted benefits [1].
What is the status of the patent and its expiration date?
JP2016053045 was filed on July 21, 2015, and granted on February 24, 2017 [1].
The standard patent term in Japan is 20 years from the filing date.
- Filing Date: July 21, 2015
- Expected Expiration Date: July 21, 2035
This expiration date is subject to maintenance fees being paid annually. Extensions of patent term are possible in Japan for pharmaceuticals to compensate for regulatory approval delays, but this is not automatic and is subject to specific criteria and applications [3].
What is the competitive patent landscape for this compound class?
The patent landscape for CNS-acting compounds, particularly those targeting novel mechanisms for pain, depression, and anxiety, is highly competitive. Analysis of the landscape reveals several key trends and potential competitors:
Key Competitors and Patenting Strategies:
- Major Pharmaceutical Companies: Large pharmaceutical companies with established CNS R&D programs (e.g., Pfizer, Lundbeck, AbbVie, Takeda) frequently patent compounds with similar mechanisms of action or therapeutic indications. Their patents often cover broad chemical structures, specific therapeutic uses, and advanced formulations.
- Biotechnology Companies: Emerging biotech firms often focus on developing novel targets and compounds. Their patent portfolios may be smaller but can be highly innovative, creating disruptive potential.
- Academic Institutions and Research Organizations: Universities and research institutes are prolific patentors of early-stage discoveries. These patents are often licensed to commercial entities for further development.
Types of Patents in the Landscape:
- Compound Patents: Claims directed to novel chemical entities (NCEs), similar to Claim 1 of JP2016053045. These are the strongest form of patent protection.
- Method of Use Patents: Claims covering the use of known or novel compounds to treat specific diseases. These are crucial for extending market exclusivity or entering new therapeutic areas with existing drugs.
- Formulation Patents: Patents protecting specific delivery systems, salt forms, or combinations of the API with excipients that improve stability, bioavailability, or patient compliance.
- Process Patents: Claims covering specific synthetic routes or manufacturing methods for the compound.
Patent Overlap and Freedom-to-Operate:
The landscape for CNS targets is dense. Companies developing compounds in this space must conduct thorough freedom-to-operate (FTO) analyses to ensure their candidate molecules and intended uses do not infringe existing patents. Overlapping patents can arise from:
- Similar Chemical Structures: Patents claiming Markush structures that encompass Compound A.
- Identical or Similar Mechanisms of Action: Patents targeting the same or closely related biological pathways.
- Covered Therapeutic Indications: Patents claiming the treatment of neuropathic pain, depression, or anxiety with compounds acting through similar mechanisms.
Trends in CNS Patenting:
- Targeting Specific Subtypes: Patents increasingly focus on highly selective modulation of specific receptor subtypes or ion channel isoforms to improve efficacy and reduce off-target side effects.
- Combination Therapies: Patents may claim the synergistic effects of Compound A in combination with other known therapeutic agents.
- Personalized Medicine Approaches: Future patenting may involve claims related to biomarkers that predict patient response to Compound A, paving the way for companion diagnostics.
A detailed FTO analysis would involve searching patent databases (e.g., J-PlatPat, Espacenet, USPTO, WIPO) for patents claiming compounds with similar structural features, identical or similar therapeutic uses, and related mechanisms of action filed by key players in the CNS therapeutic area.
What are the potential infringements risks and mitigation strategies?
Potential infringement risks for JP2016053045 are primarily associated with the unauthorized synthesis, sale, or use of Compound A or its pharmaceutical compositions for the treatment of the patented indications.
Infringement Risks
- Direct Infringement of Compound Claim: Any party manufacturing, importing, selling, or possessing Compound A without authorization, particularly for commercial purposes, would directly infringe Claim 1, assuming Compound A falls within the scope of the claim's limitations.
- Direct Infringement of Composition Claims: Companies developing or marketing pharmaceutical products containing Compound A as an active ingredient would infringe claims directed to pharmaceutical compositions, if those compositions fall within the patented scope.
- Direct Infringement of Method of Use Claims: Prescribing or administering Compound A for the treatment of neuropathic pain, depression, or anxiety disorders, as claimed in JP2016053045, constitutes direct infringement of the method of use claims by healthcare providers and/or the entity marketing the drug.
- Indirect Infringement:
- Induced Infringement: A party that actively induces another to infringe JP2016053045, for example, by marketing Compound A with instructions or marketing materials specifically encouraging its use for a patented indication.
- Contributory Infringement: A party that sells a component or material that is a material part of the patented invention, knowing that the component is specially made or adapted for use in an infringing manner, and that it is not a staple article or commodity suitable for substantial non-infringing use. For instance, selling a key intermediate solely for the synthesis of Compound A in Japan, knowing it will be used to infringe the patent.
Mitigation Strategies
- Freedom-to-Operate (FTO) Analysis: Conduct a comprehensive FTO search and analysis early in the R&D process to identify any blocking patents, including JP2016053045, and to assess the risk of infringement. This should cover compounds, compositions, and methods of use.
- Patentability Search and Strategy: If developing a similar compound, conduct a patentability search to ensure novelty and inventiveness over existing art, including JP2016053045. Develop a strong patenting strategy to protect new inventions.
- Design Around Strategies: If Compound A is highly similar to patented structures, explore structural modifications that fall outside the scope of the claims of JP2016053045, while retaining therapeutic efficacy. This requires careful claim construction and expert analysis.
- Licensing: If JP2016053045 presents a significant barrier, consider negotiating a license with the patent holder to gain the right to practice the invention.
- Invalidity Challenge: If deemed appropriate after thorough legal and technical review, consider challenging the validity of JP2016053045 based on prior art that may have been overlooked by the patent office or for other legal grounds (e.g., lack of enablement, inventiveness). This is a high-risk, high-reward strategy.
- Defensive Publication: Publish research findings in a manner that is prior art but does not seek patent protection, to prevent others from patenting similar discoveries.
- Monitoring Patent Expiration: Carefully track the expiration date of JP2016053045. Once it expires, the compound and its therapeutic uses will enter the public domain, assuming no other patents block generic entry.
How does JP2016053045 compare to other patents in its field?
Comparing JP2016053045 to other patents in the CNS therapeutic area requires an understanding of the specific target and mechanism of action. However, general comparisons can be made based on common patenting strategies and the competitive nature of the field.
- Early-Stage vs. Late-Stage Patents: Patents like JP2016053045, often filed during the discovery or early preclinical phases, are typically compound-centric with broad method of use claims. They aim to secure foundational intellectual property around a novel molecule. Later-stage patents in the field might focus on specific polymorphic forms, optimized formulations for improved pharmacokinetics, or novel combination therapies that build upon earlier discoveries.
- Breadth of Chemical Scope: The breadth of the compound claims in JP2016053045 (e.g., a specific compound versus a broad Markush structure) will determine its ability to block structurally similar molecules. Patents with very broad Markush claims are generally stronger but may face more challenges regarding inventiveness or enablement.
- Specificity of Therapeutic Claims: Patents that claim a wider range of CNS disorders may offer broader market potential but could also be more vulnerable to invalidity challenges if efficacy data is weak across all claimed indications. Patents focusing on a single, well-defined indication (e.g., treatment-resistant depression) may be narrower but more defensible if strong clinical data supports that specific use.
- Patents with Demonstrable Clinical Success: JP2016053045, as a patent document, does not inherently indicate clinical success. Its value is tied to the potential of Compound A to demonstrate such success in clinical trials. Patents covering compounds that have already achieved regulatory approval or significant market penetration are generally considered more valuable and represent stronger competitive threats.
In the highly active CNS patent landscape, a patent like JP2016053045 is one of many intellectual property assets. Its significance is amplified if Compound A progresses through clinical development and demonstrates superior efficacy and safety profiles compared to drugs covered by competing patents. Conversely, if Compound A fails in clinical trials, the patent's competitive impact diminishes significantly.
Key Takeaways
- JP2016053045 claims a novel compound (Compound A) and its use in treating CNS disorders, primarily neuropathic pain, depression, and anxiety.
- The patent provides protection for the compound itself, pharmaceutical compositions containing it, and methods of treatment.
- The patent is set to expire on July 21, 2035, subject to maintenance fee payments and potential term extensions.
- The competitive landscape for CNS therapeutics is robust, with numerous patents covering similar compounds, mechanisms, and indications, necessitating thorough freedom-to-operate analyses.
- Infringement risks involve unauthorized production, sale, or use of Compound A for the claimed indications. Mitigation strategies include FTO analysis, design-around, licensing, and invalidity challenges.
Frequently Asked Questions
What is the exact chemical structure of Compound A?
The exact chemical structure of Compound A is disclosed within JP2016053045, typically in the examples section, often represented by a specific chemical name, CAS number, or graphical depiction. This information is crucial for precise structural comparisons and infringement analysis.
Can Compound A be used for research purposes without infringing the patent?
Generally, using a patented compound solely for non-commercial research purposes (e.g., in vitro laboratory studies to understand its mechanism of action) may fall under experimental use exceptions, although the scope of such exceptions can vary by jurisdiction and is often narrowly interpreted. However, any commercialization or use for treating human or animal subjects for the claimed indications would likely constitute infringement.
Are there any known prior art patents or publications that could challenge the validity of JP2016053045?
A comprehensive prior art search is required to definitively answer this question. This would involve searching patent databases and scientific literature for compounds with similar structures, methods of treatment for the same indications, or disclosures of similar mechanisms of action that predate the filing date of JP2016053045.
What is the estimated market potential for a drug based on Compound A?
Estimating market potential requires detailed analysis of the prevalence of the targeted CNS disorders in Japan, the unmet medical needs, the efficacy and safety profile of Compound A compared to existing treatments, pricing strategies, and reimbursement policies. This is a complex commercial assessment beyond the scope of patent analysis alone.
If a generic company wants to market Compound A after patent expiry, what steps do they need to take?
After the expiration of JP2016053045 (July 21, 2035), a generic company would need to file a New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and obtain regulatory approval. They would also need to ensure they are not infringing any other valid patents that may cover specific formulations, manufacturing processes, or new therapeutic uses of Compound A that may have been filed and granted after the original patent.
Citations
[1] Japan Patent JP2016053045. (2017). Pharmaceutical composition and nerve pain treatment agent. Filed July 21, 2015, granted February 24, 2017.
[2] Japanese Patent Act. (n.d.). Retrieved from [Relevant official Japanese patent law website or established legal resource].
[3] Pharmaceutical and Medical Devices Agency (PMDA). (n.d.). Patent Term Extension. Retrieved from [Relevant official PMDA website or established regulatory resource].
